Tags : Alvogen

PharmaShots’ Key Highlights of Fourth Quarter 2019

1. Pfizer Launched its Zirabev (biosimilar, bevacizumab) in the US by the year end 2019 Date – Oct 01, 2019 Product – Zirabev (biosimilar, bevacizumab) The biosimilar was launched in the US on Dec 31, 2019 following the settlement between Genentech and Pfizer granting all global rights of the product to the Pfizer. In Sept […]Read More

Mithra Signs a License Agreement with Alvogen for its Estelle

Shots: Mithra to get up front, sales milestones, royalties and recurring revenues based on Minimal Annual Quantities (MAQ) and will manufacture Estelle at its Contract Development and Manufacturing Organization facility in Belgium. Alvogen to get exclusive commercialization rights for Mithra’s Estelle in Hong Kong and Taiwan The agreement follows its previous licensing deals for Estelle […]Read More

Alvogen to Acquire Assertio’s Gralise (gabapentin) for $127.5M

Shots: Assertio to receive $127.5M including $75M up front in cash and $52.5M as royalties when Gralise net sales reach $75M while Alvogen will get all responsibilities related to the product. The transaction is expected to be close in Jan’2020 The acquisition allows Assertio to focus on its growth product, Cambia and Zipsor and improve […]Read More

Yas Holding Collaborates with Alvogen to Commercialize its Generic Portfolio

Shots: Yas Holding entered into an exclusive license and distribution agreement with Alvogen to commercialize its targeted generic pharmaceuticals portfolio in MENA region The collaboration will expand Alvogen’s presence in the MENA region including Gulf, KSA, Levant, North Africa and Sub-Saharan Africa and will improve clinical outcomes and QoL of patients in the MENA region […]Read More

Insights+: The US FDA New Drug Approvals in September and

The US FDA’s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 35 new products so far in 2019. In 2018 FDA approved 59 novel products including 42 New Chemical Entities and 17 Biologics while breaking its last year’s record of approvals. However, there is a significant […]Read More

Insights+ Key Biosimilars Events of October 2019

Biosimilars are key alternatives for costly Biologics therapies and saving millions of dollars of patients in multiple diseases. Hence physicians are likely to adopt biosimilars “a reference product to biologics” possessing similar therapeutic properties in terms of potency, safety, and efficacy to original biologic products. Our team at PharmaShots has summarized key events of the […]Read More

PharmaShots Weekly Snapshot (October 21-25, 2019)

1. Urology San Antonio Collaborates with Anixa Biosciences on Ccheck Prostate Cancer Study Published: Oct 25, 2019 | Tags: Urology San Antonio, Collaborates, Anixa Biosciences, Ccheck, Prostate Cancer Study 2. NHS England Signs an Agreement with Vertex to Access All Licensed Cystic Fibrosis Therapies Published: Oct 24, 2019 | Tags: NHS England, Signs, Agreement, Vertex, Access, Licensed, […]Read More

Zentiva to Acquire Alvogen’s Generics and OTC Business in Central

Shots: Zentiva acquires Alvogen’s CEE market consisting of 200+ generics and OTC therapies across multiple therapeutics areas which include brands like Lactacyd, Persen, EuBiotic. The transaction is expected to be closed in Q1’20 The focus of the acquisition is to combine two leading branded generics and OTC business in the CEE region and will strengthen […]Read More

Alvogen Signs an Exclusive Commercialization Agreement with Three Pharma Companies

Shots: Alvogen collaborates with PharmBio, Kamada and Jamp to commercialize PF708 for the treatment of osteoporosis in South Korea, Israel and Canada respectively The focus of the collaboration is to build strong commercial networks in South Korea, Israel and Canada and to gain commercial expertise within the territories PF708 is a biosimilar referencing Eli Lilly’s […]Read More

PharmaShots Weekly Snapshot (October 07-11, 2019)

OraSure Technologies’ Rapid Diagnostic OraQuick Ebola Rapid Antigen Test Receives the US FDA Marketing Approval for Detection of Ebola Virus Antigens Published: Oct 10, 2019 | Tags: Diagnostic, Oraquick Ebola Rapid Antigen Test, Orasure Technologies, Rapid, Receives, The US FDA, Marketing, Approval, Detection, Ebola Virus Antigens 2. Alnylam Reports Submission of MAA to Brazilian Health Regulatory […]Read More